首页 > 药物分析学报（英文版） > Clinically and orally compatible formulation-manufactured DDX5(p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer

Clinically and orally compatible formulation-manufactured DDX5(p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer

导出在线阅读解读下载全文终端阅读

二维码有效期 120s

点击刷新

注：终端设备浏览有效期：

学术成果认领

翻译打印收藏纠错

摘要Our recent breakthrough discovery demonstrated that the anti-cancer drug FL118 tightly binds to and then dephosphorylates and degrades the oncogenic protein DEAD-box helicase 5(DDX5),lead-ing to the inhibition of DDX5 downstream targets(e.g.,survivin,myeloid cell leukemia 1(Mcl-1),X-linked inhibitor of apoptosis(XIAP),c-Myc,mutant Kras,etc.)[1].FL118 is a molecular glue(MG)that can alter the interactomes of two or more non-interacting proteins[2].Thus,FL118 exhibits high efficacy against colorectal and pancreatic cancer xenograft tumors[1,3].

作者 Xiang Ling ^[1] Wenjie Wu ^[1] Li Yan ^[2] Leslie Curtin ^[3] Melanie M.Farrauto ^[3] Sandra Sexton ^[3] Anmbreen Jamroze ^[4] Changjun Yu ^[5] Christos Fountzilas ^[6] Dean G.Tang ^[7] Fengzhi Li ^[8] 学术成果认领

作者单位 Department of Pharmacology & Therapeutics,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Canget BioTekpharma LLC,Buffalo,New York,14203,USA ^[1] Department of Biostatistics & Bioinformatics,Roswell Park Comprehensive Cancer Center Buffalo,New York,14263,USA ^[2] Comparative Oncology Shared Resources,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA ^[3] Department of Pharmacology & Therapeutics,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA ^[4] California Institute of Technology,Pasadena,CA,91125,USA ^[5] Department of Medicine,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Developmental Therapeutics(DT)Program,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Pancreatic Cancer Research Center,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA ^[6] Department of Pharmacology & Therapeutics,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Developmental Therapeutics(DT)Program,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Genitourinary(GU)Oncology Research Center,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA ^[7] Department of Pharmacology & Therapeutics,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Developmental Therapeutics(DT)Program,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Pancreatic Cancer Research Center,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA;Genitourinary(GU)Oncology Research Center,Roswell Park Comprehensive Cancer Center,Buffalo,New York,14263,USA ^[8]

栏目名称

Short Communications

DOI 10.1016/j.jpha.2024.101001

发布时间 2025-01-25（万方平台首次上网日期，不代表论文的发表时间）

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交